InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

- Current share price for RCE : $0.380

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$116 HREC Approves Comparator Study for Pivotal Phase 3 DFI 19 Aug 2026 11:02AM $0.380 $0.380 fallen by 0%
$116 Change of Director's Interest Notices (x4) 6 Aug 2026 4:55PM $0.380 $0.380 fallen by 0%
$116 Cleansing Notice 4 Aug 2026 4:12PM $0.375 $0.380 risen by 1.33%
$116 Application for quotation of securities - RCE 3 Aug 2026 8:23AM $0.370 $0.380 risen by 2.70%
$116 Completion of Share Purchase Plan and Shortfall Notice 31 Jul 2026 11:32AM $0.385 $0.380 fallen by 1.30%
$116 Application for quotation of securities - RCE 31 Jul 2026 11:30AM $0.385 $0.380 fallen by 1.30%
$116 Notice of General Meeting/Proxy Form 31 Jul 2026 9:04AM $0.375 $0.380 risen by 1.33%
$116 U.S. Government Releases US$66.9B AMR Biodefense Strategy 30 Jul 2026 10:38AM $0.375 $0.380 risen by 1.33%
$116 Investor Webinar - Q4 FY26 Investor Presentation Deck 21 Jul 2026 12:50PM $0.363 $0.380 risen by 4.83%
$116 Investor Webinar - 2.30PM (AEST) 21 July 2026 21 Jul 2026 12:27PM $0.355 $0.380 risen by 7.04%
$116 Quarterly Activities/Appendix 4C Cash Flow Report 21 Jul 2026 12:20PM $0.355 $0.380 risen by 7.04%
$116 Update - Proposed issue of securities - RCE 20 Jul 2026 9:33AM $0.380 $0.380 fallen by 0%
$116 Extension to Share Purchase Plan Closing Date 20 Jul 2026 9:29AM $0.380 $0.380 fallen by 0%
$116 Vietnamese Patent Granted for RECCE Anti-Infectives 14 Jul 2026 8:56AM $0.390 $0.380 fallen by 2.56%
$116 Share Purchase Plan - Letter and Offer Booklet 6 Jul 2026 9:06AM $0.375 $0.380 risen by 1.33%
$116 Cleansing Notice 3 Jul 2026 2:31PM $0.370 $0.380 risen by 2.70%
$116 Application for quotation of securities - RCE 3 Jul 2026 2:25PM $0.370 $0.380 risen by 2.70%
$116 Notification of cessation of securities - RCE 2 Jul 2026 4:26PM $0.375 $0.380 risen by 1.33%
$116 Cleansing Notice 1 Jul 2026 11:30AM $0.385 $0.380 fallen by 1.30%
$116 Application for quotation of securities - RCE 1 Jul 2026 11:24AM $0.395 $0.380 fallen by 3.80%
$116 Application for quotation of securities - RCE 1 Jul 2026 11:10AM $0.385 $0.380 fallen by 1.30%
$116 Application for quotation of securities - RCE 1 Jul 2026 11:04AM $0.375 $0.380 risen by 1.33%
$116 AUD $3.7M Income Tax Refund Received 1 Jul 2026 9:07AM $0.405 $0.380 fallen by 6.17%
$116 Proposed issue of securities - RCE 26 Jun 2026 6:00PM $0.400 $0.380 fallen by 5%
$116 RCE Investor Presentation 26 Jun 2026 10:35AM $0.375 $0.380 risen by 1.33%

1 - 25 of 725 results

Page 1 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.